Despite positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial opposition from managed care entities. These insurers are https://janewaga587213.thenerdsblog.com/48157593/company-s-vyndamax-faces-is-meeting-pbm-challenges-the-examination-of-reimbursement-battles